ATE255125T1 - Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren von 5-alpha-reduktase - Google Patents

Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren von 5-alpha-reduktase

Info

Publication number
ATE255125T1
ATE255125T1 AT96202933T AT96202933T ATE255125T1 AT E255125 T1 ATE255125 T1 AT E255125T1 AT 96202933 T AT96202933 T AT 96202933T AT 96202933 T AT96202933 T AT 96202933T AT E255125 T1 ATE255125 T1 AT E255125T1
Authority
AT
Austria
Prior art keywords
alpha
androstan
aza
beta
substituted
Prior art date
Application number
AT96202933T
Other languages
English (en)
Inventor
Raman K Bakshi
Gary H Rasmusson
Richard L Tolman
Gool F Patel
Georgianna Harris
Donald W Graham
Bruce E Witzel
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE255125T1 publication Critical patent/ATE255125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
    • C07C59/82—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings the keto group being part of a ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96202933T 1992-05-20 1993-05-19 Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren von 5-alpha-reduktase ATE255125T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88657292A 1992-05-20 1992-05-20

Publications (1)

Publication Number Publication Date
ATE255125T1 true ATE255125T1 (de) 2003-12-15

Family

ID=25389283

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93303882T ATE156838T1 (de) 1992-05-20 1993-05-19 Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren 5-alpha-reduktases
AT96202933T ATE255125T1 (de) 1992-05-20 1993-05-19 Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren von 5-alpha-reduktase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93303882T ATE156838T1 (de) 1992-05-20 1993-05-19 Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren 5-alpha-reduktases

Country Status (14)

Country Link
US (1) US5710275A (de)
EP (2) EP0778284B1 (de)
JP (1) JPH06100587A (de)
CN (1) CN1087092A (de)
AT (2) ATE156838T1 (de)
CA (1) CA2096616A1 (de)
DE (2) DE69313018T2 (de)
DK (1) DK0572166T3 (de)
ES (2) ES2210336T3 (de)
GR (1) GR3024884T3 (de)
IL (1) IL105715A (de)
MX (1) MX9302932A (de)
WO (1) WO1993023420A1 (de)
ZA (1) ZA933497B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023039A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. Substituted 4-aza-5a-androstan-ones as 5a-reductase inhibitors
US5639741A (en) * 1992-05-20 1997-06-17 Merck & Co., Inc. 17-amino substituted 4-azasteroid 5α-reductase inhibitors
US5510351A (en) * 1992-05-20 1996-04-23 Merck & Co., Inc. Delta-17 and delta-20 olefinic and saturated 17 beta-substituted 4-aza-5 alpha-androstan-ones as 5 alpha reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
EP0641209A4 (de) * 1992-05-20 1995-08-23 Merck & Co Inc Neue 17-ester-, amid- und ketonderivate von 3-oxo-4-azasteroiden als 5-alpha-reduktaseinhibitoren.
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
US5620986A (en) * 1992-05-20 1997-04-15 Merck & Co., Inc. 17 urea, thiourea, thiocarbamyl and carbamyl4-azasteroid 5-reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
SK140494A3 (en) * 1992-05-21 1995-07-11 Endorecherche Inc Inhibitors of testosterone 5-alpha-reductase activity
AU5323694A (en) * 1992-10-06 1994-04-26 Merck & Co., Inc. 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
ATE203162T1 (de) * 1992-12-18 2001-08-15 Merck & Co Inc Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4- aza-5 alpha-androst-1-en-3-one
EP0711164B1 (de) * 1993-06-28 1997-09-17 Merck & Co. Inc. 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
US5438061A (en) * 1993-07-16 1995-08-01 Merck & Co., Inc. 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
DE69417925T2 (de) * 1993-11-04 1999-11-25 Merck & Co., Inc. 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
GB9415178D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 4-azasteroids with side-chain fluoroketones
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
EP0862556B1 (de) * 1995-10-23 2001-09-05 Merck & Co., Inc. 17-alkyl-7-substituierte-4-aza-steroidderivate
US6365597B1 (en) 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5872126A (en) * 1996-09-06 1999-02-16 Merck & Co., Inc. Methods and compositions for treating preterm labor
AU7327798A (en) * 1997-05-07 1998-11-27 Novopharm Limited 4-aza-steroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
JP4563032B2 (ja) * 2002-01-15 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体モジュレータとしての１７−ヒドロキシ−４−アザ−アンドロスタン−３−オン
JP4832303B2 (ja) * 2003-05-07 2011-12-07 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体モジュレータおよびこれらの使用
AU2004256075B2 (en) * 2003-06-30 2008-12-04 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
AU2004255200A1 (en) * 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
AU2004259664B2 (en) * 2003-06-30 2009-05-28 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
JP2007521292A (ja) * 2003-06-30 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体モジュレータとしての１７−アセトアミド−４−アザステロイド誘導体
JP2007505120A (ja) * 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節因子としての１７−複素環式−４−アザステロイド誘導体。
CA2537663A1 (en) 2003-09-10 2005-03-24 Merck & Co., Inc. 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
CN1942187A (zh) * 2004-04-08 2007-04-04 默克公司 作为雄激素受体调节剂的17β－乙酰胺－4－氮杂甾体化合物
CN100355772C (zh) * 2005-12-28 2007-12-19 天津大学 具有5α－还原酶抑制活性的甾体化合物及其制备方法
WO2011131543A1 (en) * 2010-04-20 2011-10-27 Syngenta Participations Ag Process for the preparation of pyrazole carboxylic acid amides
CN111175410A (zh) * 2020-02-12 2020-05-19 武汉大学 N-甲基苯乙胺及其同位素试剂在羧基化合物检测中的应用
WO2022261774A1 (en) * 2021-06-16 2022-12-22 UNIVERSITé LAVAL Novel inhibitors of 17b-hsd7 and uses thereof
CN121108234B (zh) * 2025-11-13 2026-02-24 安徽益普克医药科技发展有限公司 一种5α-还原酶长效衍生物及其制备方法与用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4859681A (en) * 1984-02-27 1989-08-22 Merck & Co., Inc. 17 α-Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
ATE67503T1 (de) * 1984-02-27 1991-10-15 Merck & Co Inc 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
CA2084799C (en) * 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5543406A (en) * 1991-12-20 1996-08-06 Glaxo Wellcome, Inc. Inhibitors of 5-α-testosterone reductase
US5215894A (en) * 1992-02-25 1993-06-01 Merck & Co., Inc. Biological process for producing 17β-N-monosubstituted carbamoyl-11-oxo-4-aza-5-α-androst-3-one testosterone-5-α reductase inhibitors
CZ283894A3 (en) * 1992-05-20 1995-09-13 Merck & Co Inc 7beta-substituted 4-aza-5alpha-cholestanones, their use for the preparation of pharmaceutical preparations and pharmaceutical compositions containing thereof
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
ATE195530T1 (de) * 1992-05-20 2000-09-15 Merck & Co Inc 17-ether und thioether von 4-aza-steroiden
US5510351A (en) * 1992-05-20 1996-04-23 Merck & Co., Inc. Delta-17 and delta-20 olefinic and saturated 17 beta-substituted 4-aza-5 alpha-androstan-ones as 5 alpha reductase inhibitors useful in the prevention and treatment of hyperandrogenic disorders
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
EP0641209A4 (de) * 1992-05-20 1995-08-23 Merck & Co Inc Neue 17-ester-, amid- und ketonderivate von 3-oxo-4-azasteroiden als 5-alpha-reduktaseinhibitoren.
SK140494A3 (en) * 1992-05-21 1995-07-11 Endorecherche Inc Inhibitors of testosterone 5-alpha-reductase activity
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents

Also Published As

Publication number Publication date
ES2210336T3 (es) 2004-07-01
DE69333317D1 (de) 2004-01-08
DE69313018T2 (de) 1998-02-19
AU3869893A (en) 1993-11-25
EP0778284A2 (de) 1997-06-11
IL105715A0 (en) 1993-09-22
CN1087092A (zh) 1994-05-25
ATE156838T1 (de) 1997-08-15
DE69333317T2 (de) 2004-08-19
GR3024884T3 (en) 1998-01-30
MX9302932A (es) 1995-01-31
IL105715A (en) 1997-07-13
EP0778284A3 (de) 1997-08-13
EP0572166B1 (de) 1997-08-13
JPH06100587A (ja) 1994-04-12
ZA933497B (en) 1993-12-14
EP0572166A1 (de) 1993-12-01
CA2096616A1 (en) 1993-11-21
WO1993023420A1 (en) 1993-11-25
DK0572166T3 (da) 1997-09-01
EP0778284B1 (de) 2003-11-26
ES2106965T3 (es) 1997-11-16
DE69313018D1 (de) 1997-09-18
US5710275A (en) 1998-01-20
AU662224B2 (en) 1995-08-24

Similar Documents

Publication Publication Date Title
ATE255125T1 (de) Neue 7-beta-substituierte-4-aza-5-alpha-androstan-3- nen als inhibitoren von 5-alpha-reduktase
DE69313921D1 (de) Neue 7-Beta-substituierte-4-Aza-5-Alpha-Cholestan-Onen als Inhibitoren 5-Alpha-Reduktases
DE69128516D1 (de) Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer
DE69331774D1 (de) 7-Substituierte-8-substituierte-9-substituierte Amino-7-Demethyl-6-Deoxy-Tetracycline als antibiotische Mittel
DE69333179D1 (de) Stabilisierung von Polybutylenterephthalat-Polyester Mischungen
DE69330733D1 (de) 9-[(Substituierte Glycyl)amido]-6-demethyl-6-deoxytetracycline als antibiotische Mittel
DE4395273T1 (de) Gemische von als H¶2¶S-Scavenger geeigneten Hexahydrotriazinen
DE69021530D1 (de) Neue Derivate von A-nor-3-Carboxysteroiden.
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
ATE219938T1 (de) Neue 4-arylpiperazine und 4-arylpiperidine
DE69319679D1 (de) Eingabe von Sonderbuchstaben
ATE174895T1 (de) Aromatische inhibitoren von acetylcholinesterase
DE69328166D1 (de) Beseitigung von schmutzstoffen
ES2179254T3 (es) 1-poliarilpirazoles plaguicidas.
DK0642506T3 (da) Heterocyclisk disubstituerede sulfonaminocarbonylforbindelser
DE69313554D1 (de) Verwendung von Tetrahydro-4-methyl-2-phenyl-2H-pyran als Riechstoff
DE59305800D1 (de) Werkzeug zur behandlung von oberflächen von bauteilen
ATE136884T1 (de) Neue 2-mercaptomethylen-tetrahydronaphthalin- und -indan-2-carboxamide als enkephalinaseinhibitoren
DE69716598D1 (de) Stabilisierung von anstrichen durch spiroindanderivaten
DE59303840D1 (de) Schabenbekämpfungsverfahren und Mittel zur Bekämpfung von Schaben
DE69404145D1 (de) Zusammensetzungen von stoffen
DE3888031D1 (de) Homocyclostatin und Cyclostatin enthaltende Polypeptide als Antihypertensiva.
ATE149837T1 (de) Gebrauch von oxatomide als antitussivum
FI925604A0 (fi) Anordning i stroemmande vatten
ATE92755T1 (de) Phenol-thioether als inhibitoren von 5lipoxygenase.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties